Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.

ABSTRACT:

Background

Onchocerciasis ("river blindness"), is a neglected tropical disease caused by the filarial nematode Onchocerca volvulus and transmitted to humans through repeated bites by infective blackflies of the genus Simulium. Moxidectin was approved by the United States Food and Drug Administration in 2018 for the treatment of onchocerciasis in people at least 12 years of age. The pharmacokinetics of orally administered moxidectin in 18- to 60-year-old men and women infected with Onchocerca volvulus were investigated in a single-center, ivermectin-controlled, double-blind, randomized, single-ascending-dose, ascending severity of infection study in Ghana.

Methodology/principal findings

Participants were randomized to either a single dose of 2, 4 or 8 mg moxidectin or ivermec

SUBMITTER: Tan B 

PROVIDER: S-EPMC8986118 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature